DAX26.402 +0,3%Est506.556 +0,3%MSCI World4.343 -0,1%Top 10 Crypto8,2600 -0,5%Nas26.588 +0,5%Bitcoin55.185 +0,4%Euro1,1541 +0,1%Öl87,08 -2,1%Gold4.394 -0,3%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
SpaceX A42D4F Rheinmetall 703000 NVIDIA 918422 Siemens Energy ENER6Y SAP 716460 Infineon 623100 Deutsche Telekom 555750 TKMS thyssenkrupp Marine Systems TKMS00 Micron Technology 869020 Lufthansa 823212 Allianz 840400 Microsoft 870747 Deutsche Bank 514000 Nebius A1JGSL Commerzbank CBK100
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX höher -- Wall Street höher erwartet -- thyssenkrupp verfehlt Erwartungen -- RWE-Bilanz überzeugt -- Birkenstock, Microsoft, Salesforce, Alphabet, Goldpreis, SpaceX, D-Wave im Fokus
Top News
RWE-Aktie gewinnt: Halbjahresbilanz überzeugt - Verschuldung bleibt im Rahmen RWE-Aktie gewinnt: Halbjahresbilanz überzeugt - Verschuldung bleibt im Rahmen
KI-Investitionen: Was der Rücksetzer für deutsche Nebenwerte bedeutet KI-Investitionen: Was der Rücksetzer für deutsche Nebenwerte bedeutet
Suche...
Jetzt kostenlos
bei finanzen.net anmelden
Watchlists & Musterdepots Tools & integriertes Trading Newsletter, Trading-Desk uvm.
Schon einen Account? Anmelden
Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Orphan Synergy Europe - Pharma SA Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
3,40 EUR +0,06 EUR +1,80 %
STU
4,40 EUR +0,02 EUR +0,34 %
LSE
finanzen.net zero
Orphan Synergy Europe - Pharma SA jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.77,71 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA14QXP

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINFR0012127173

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolORPOF

Orphan Synergy Europe - Pharma SA Aktien News

DatumMeistgelesen
GlobeNewswireADJOURNMENT OF THE GENERAL MEETING INITALLY CONVENED ON JUNE 25, 2025
GlobeNewswireUPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETING
GlobeNewswireOse Immunotherapeutics : Documents made available to the shareholders for the combined general meeting of June 25th, 2025
Wer­bungOrphan Synergy Europe - Pharma SA-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
GlobeNewswireOSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology
GlobeNewswireOSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer Vaccine Tedopi® in Pancreatic Cancer and Non-Small Cell Lung Cancer
GlobeNewswireOSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPa Blockade in Two Ongoing Trials
GlobeNewswireOSE Immunotherapeutics Announces Strategic Collaboration to Pioneer Novel mRNA Technologies
GlobeNewswireOSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab
GlobeNewswireImmuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025
GlobeNewswireOSE Immunotherapeutics Highlights Abstracts Selected for Presentation at ASCO 2025
GlobeNewswireOSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025
GlobeNewswireOSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025
GlobeNewswireOSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswireOSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer
GlobeNewswireOSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD
GlobeNewswireOSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO
GlobeNewswireOSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic Colitis In Oral Presentation at 20th Congress of ECCO
GlobeNewswireOSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy
GlobeNewswireOSE Immunotherapeutics Presents Three Abstracts for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO
GlobeNewswireOSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer
GlobeNewswireOSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2 Induction Results in Ulcerative Colitis at 20th Congress of ECCO
GlobeNewswireOSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi®
GlobeNewswireOSE Immunotherapeutics Strengthens Leadership and Executive Committee
GlobeNewswireOSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis
GlobeNewswireOSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index
GlobeNewswireOSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update
GlobeNewswireOSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer
GlobeNewswireOSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis
GlobeNewswireBoehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371
GlobeNewswireOSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’
GlobeNewswireOSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies
GlobeNewswireOSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco (June 18 – 21)
GlobeNewswireOSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s Growth
GlobeNewswireOSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin Besse
GlobeNewswireOSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant
GlobeNewswireOSE Immunotherapeutics Provides Business and Corporate Update
GlobeNewswireOSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases
GlobeNewswireOSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective
GlobeNewswireOSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer
GlobeNewswireOSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology

Orphan Synergy Europe - Pharma SA News

Orphan Synergy Europe - Pharma SA News: auf dieser Seite finden Sie alle Orphan Synergy Europe - Pharma SA News und Nachrichten zur Orphan Synergy Europe - Pharma SA Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Orphan Synergy Europe - Pharma SA News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Orphan Synergy Europe - Pharma SA News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.

Information

Die Handels- und Depotfunktionen in diesem Broker Cockpit werden für Finanzinstrumente von der Finanzen.net Zero GmbH als vertraglich gebundener Vermittler der DonauCapital Wertpapier GmbH (§ 3 Abs. 2 WpIG) bereitgestellt; bei Kryptowerten werden die Handels- und Depotfunktionen in diesem Broker Cockpit ausschließlich von der DonauCapital Wertpapier GmbH bereitgestellt. Die Finanzen.net GmbH stellt ausschließlich den technischen Rahmen bereit und ist in die Wertpapier- und Kryptodienstleistung nicht einbezogen.